Rational Use of New and Emerging Agents for Hepatitis Delta Virus

Hepatitis delta virus (HDV) is the most severe form of viral hepatitis and warrants new treatment options for better efficacy and tolerability. In part 2 of this 2-part podcast series, hear Heiner Wedemeyer, MD, and Cihan Yurdaydin, MD, discuss their thoughts on new and emerging treatment options for HDV and rational use of these new agents. Their discussion includes:Assembly inhibitors (eg, lonafarnib)Entry inhibitors (eg, bulevirtide)Interferon lambdaNucleic acid polymersSmall interfering RNA (siRNA) agentsPresenters: Heiner Wedemeyer, MDProfessor and ChairmanDepartment of Gastroenterology, Hepatology, and EndocrinologyHannover Medical SchoolHannover, GermanyCihan Yurdadin, MDProfessor and Chief Department of Gastroenterology and HepatologyKoç University Medical SchoolIstanbul, TurkeyLink to full program:https://bit.ly/365VUlG Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

There are no comments yet.

Please log in to write the first comment.